pirtobrutinib news

All news on pirtobrutinib (also known as Jaypirca): plants, production capacities, investments and involved companies.

26 June 2026

Lilly's Jaypirca recommended by CHMP for EU approval in CLL across all therapy lines

CHMP issued a positive opinion for pirtobrutinib for adults with CLL across all lines of therapy; application now referred to the European Commission for final decision.
14 June 2026

Lilly: Jaypirca plus venetoclax‑rituximab lowers progression risk 45% in relapsed/refractory CLL/SLL

Phase 3 BRUIN CLL-322 found adding pirtobrutinib to a two‑year venetoclax+rituximab regimen reduced progression or death by 45% versus venetoclax+rituximab alone.

Who will be producing pirtobrutinib in the future?

Find out with chemXplore Alpha

Learn more